• Explore /
  • Poster
  • / A phase 2 trial of mosunetuzumab with lenalidomide augmentation as first-line therapy for follicular (FL) and marginal zone lymphoma (MZL).

A phase 2 trial of mosunetuzumab with lenalidomide augmentation as first-line therapy for follicular (FL) and marginal zone lymphoma (MZL).

Abstract Poster

Authors

Adam Olszewski

Adam J Olszewski

Brown University, Providence, RI

Adam J Olszewski , Scott F. Huntington , Thomas Ollila , Ari Pelcovits , Jessica B. McMahon , Inna Yakirevich , Ashlee Sturtevant , Anna Chorzalska , John Morgan , Patrycja Dubielecka

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT04792502

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS7588)

DOI

10.1200/JCO.2023.41.16_suppl.TPS7588

Abstract #

TPS7588

Poster Bd #

134a

Abstract Disclosures

Similar Posters

First Author: Yucai Wang

First Author: Umberto Vitolo

First Author: Loretta J. Nastoupil

First Author: Pier Luigi Zinzani